July is Dry Eye Awareness Month, according to the National Eye Institute, which has published a fact sheet about the disease on its website.
Dry eye, occurring when the quantity and/or quality of tears fails to keep the surface of the eye lubricated, can result from a multitude of causes including medications, advanced age, rosacea and autoimmune disorders, the NEI said. Treatment options for dry eye disease are evolving as research continues into how best to address it.
Here are some articles and blogs posted to Healio.com/OSN in 2019 regarding dry eye:
Voclosporin ophthalmic solution yields positive results for dry eye
Aurinia Pharmaceuticals’ voclosporin ophthalmic solution demonstrated positive results in an exploratory phase 2 study evaluating the efficacy, safety and tolerability of the treatment for dry eye syndrome. Read more.
Allegro introduces dry eye treatment candidate
Allegro Ophthalmics has added ALG-1007, a new anti-integrin drug candidate for the treatment of dry eye disease, to its portfolio. The topical agent is under evaluation in a phase 2 study outside of the U.S. and is the company’s first exploratory drug not in the retina space. Read more.
Dry eye, depression and LASIK: Serious thoughts about a serious issue
In the fall of 2018, there were two tragic suicides that were publicly linked to dry eye disease and LASIK. Read more.
NOV03 shows positive phase 2 results for evaporative dry eye
NOV03, a novel, single chemical entity molecule, showed improvement in evaporative dry eye symptoms in the phase 2 SEECASE trial. Read more.
BLOG: Don ’ t wait for dry eye patients — find them and prevent disease progression
If you wait for patients to tell you they have dry eye, you may be waiting until it’s too late. Read more.
Dompé initiates dry eye trial
Dompé has enrolled the first patient in a phase 2b clinical trial of its recombinant human nerve growth factor eye solution for the treatment of dry eye disease. Read more.